U.s. NeuroSurgical(OTC) USNU

U.S. NeuroSurgical Holdings, Inc. operates specialized facilities for stereotactic radiosurgery, utilizing advanced gamma knife technology. This innovative approach effectively treats brain tumors and various cerebral malformations, positioning the company as a key player in the healthcare sector.

Products and Services

• Specialized facilities for stereotactic radiosurgery
• Gamma knife technology for non-invasive treatments
• Focus on brain tumor and cerebral malformation therapies

Growth Outlook

• Market demand for non-invasive surgical options is increasing
• Expansion plans to enhance service offerings and reach
• Potential partnerships with healthcare providers for growth

Financial Highlights

• Q2 2026 revenue of $1.31 million, showing consistent performance
• Trailing twelve months (TTM) gross profit margin at 10.8%
• Cash and cash equivalents of $1.3 million as of June 30, 2026

U.S. NeuroSurgical Holdings, Inc. has established itself in the medical care facilities industry, focusing on innovative treatment options for neurological conditions. The company's use of gamma knife technology allows for precise, non-invasive procedures, which are increasingly sought after in modern healthcare. The growth outlook appears promising, driven by rising demand for non-invasive surgical solutions and potential collaborations with healthcare providers. Recent financial performance indicates a stable revenue stream, with Q2 2026 revenue reaching $1.31 million. The gross profit margin of 10.8% reflects the company's ability to manage costs effectively while delivering specialized services. With a solid cash position of $1.3 million as of June 30, 2026, U.S. NeuroSurgical Holdings, Inc. is well-positioned to explore further growth opportunities and enhance its market presence. The combination of innovative technology and a strategic focus on expanding service offerings may attract interest from potential investors looking for opportunities in the healthcare sector.